CF 301

Drug Profile

CF 301

Alternative Names: CF-301

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Antibacterials; Enzymes
  • Mechanism of Action Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacteraemia
  • No development reported Skin and soft tissue infections

Most Recent Events

  • 25 May 2017 Phase-II clinical trials in Bacteraemia (Adjunctive treatment) in North America, South America, Europe (IV)
  • 22 Apr 2017 Adverse events data from the phase-I CF-301-101 trial in Bacteraemia presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top